Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA approves Novo Nordisk A/S drug for blood clotting disorder - Reuters


Monday, 23 Dec 2013 02:14pm EST 

U.S. Food and Drug Administration:Says it has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder known as congenital Factor XIIIA-subunit deficiency - Reuters.Says Tretten was studied in 77 patients with the disorder and was effective in preventing bleeding in 90 percent of the patients when given monthly. 

Company Quote

45.71
0.47 +1.04%
3:46pm EDT